Loading
Life sciences · Journal article
Journal of Nanobiotechnology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hypoxia within the tumor microenvironment severely compromises the therapeutic efficacy of photodynamic therapy (PDT) by limiting oxygen-dependent reactive oxygen species (ROS) generation. Although extensive efforts have been devoted to oxygen-supplementation strategies, most existing approaches provide only transient hypoxia relief and are hindered by limited oxygen-loading capacity, premature oxygen leakage, and insufficient catalytic efficiency. Herein, we report a carrier-free self-assembly nanodrug (BBR-Ce6 NPs) that enhances PDT through a durable oxygen-economizing strategy by reducing mitochondrial oxygen consumption rather than directly supplying oxygen. The nanodrug is composed of the mitochondria-targeting oxidative phosphorylation (OXPHOS) inhibitor berberine (BBR) and the clinically used photosensitizer chlorin e6 (Ce6), which spontaneously co-assemble via synergistic π-π stacking and hydrogen-bonding interactions to form stable nanoparticles with high drug-loading efficiency. Benefiting from reversible noncovalent interactions, BBR-Ce6 NPs gradually disassemble within the mildly acidic tumor microenvironment, enabling tumor-responsive drug release. Following cellular internalization, BBR preferentially accumulates in mitochondria and inhibits mitochondrial complex I activity, thereby suppressing OXPHOS, reducing cellular oxygen consumption, and durably alleviating tumor hypoxia. This oxygen-sparing effect markedly enhances Ce6-mediated ROS generation and significantly improves PDT efficacy both in vitro and in vivo. In addition, the carrier-free formulation minimizes excipient-associated toxicity while simplifying nanoparticle fabrication. Collectively, this study establishes a safe and sustained hypoxia-relief strategy for enhancing PDT efficacy and offers a versatile nanoplatform for combining natural mitochondrial modulators with photosensitizers to overcome hypoxia-associated resistance of PDT in cancer treatment.